US regulatory framework for rare plasma protein diseases

Abstract

FDA encourages the development of products that demonstrate promise for the treatment of rare plasma protein disorders. This is accomplished through a program of regulatory provisions, financial incentives, clinical trials designed to address small patient populations, and measures to increase the number of patients under study.